Table 1.
Characteristics of the study cohort of patients without immune-mediated inflammatory disease (IMID) and according to the subsequent diagnosis of IMID or other condition
| All (N=108) | New-onset IMID (N=33) | No new-onset IMID (N=75) | P value* | |
| Inpatients | 88 (81) | 13 (39) | 75 (100) | <0.0001 |
| Outpatients | 20 (19) | 20 (61) | 0 (0) | |
| M | 65 (60) | 20 (61) | 45 (60) | 0.95 |
| F | 43 (40) | 13 (39) | 30 (40) | |
| Vaccine type† | 0.07 | |||
| BNT162b2 | 71 (66) | 18 (54) | 53 (71) | |
| mRNA-1273 | 11 (10) | 4 (12) | 7 (9) | |
| ChAdOx1 | 18 (17) | 10 (30) | 8 (11) | |
| Ad26.COV2.S | 7 (6) | 1 (4) | 6 (8) | |
| Unknown | 1 (1) | 0 (0) | 1 (1) | |
| Doses received prior to IMID diagnosis | ||||
| 1 | NA | 9 | NA | NA |
| 2 | 16 | |||
| Full-schedule+booster‡ | 8 | |||
| Age, mean±SD | 64±17 | 62±16 | 65±17 | 0.42 |
| In-hospital stay, days, mean±SD | 14±9 | 12±9 | 15±9 | |
| Comorbidities, median (range) | 3 (0–7) | 2 (0–7) | 3 (0–6) | 0.14 |
| Type of comorbidity, N (%) of patients | ||||
| Cardiovascular diseases | 17 (52) | 49 (65) | 0.18 | |
| Respiratory diseases | 2 (6) | 13 (17) | 0.12 | |
| Metabolic disorders | 11 (33) | 16 (21) | 0.18 | |
| Gastrointestinal diseases | 5 (15) | 18 (24) | 0.3 | |
| Renal diseases | 2 (6) | 9 (12) | 0.34 | |
| Neurological diseases | 4 (12) | 12 (16) | 0.6 | |
| Endocrine diseases | 12 (36) | 24 (32) | 0.66 | |
| Urogenital diseases | 2 (6) | 7 (9) | 0.57 | |
| Non-inflammatory MSK diseases | 3 (9) | 11 (15) | 0.43 | |
| Neoplasms | 4 (12) | 8 (11) | 0.82 | |
| Dermatological diseases | 1 (3) | 0 (0) | 0.54 | |
| Psychiatric diseases | 0 (0) | 3 (4) | 0.8 | |
| Ophtalmological diseases | 0 (0) | 3 (4) | 0.8 | |
| Haematological disorders | 1 (3) | 2 (3) | 0.91 | |
| ENT diseases | 0 (0) | 3 (4) | 0.8 |
Values are shown as number (%) of patients unless otherwise stated.
BNT162b2, vaccine developed by Pfizer/BioNTech; mRNA1273, vaccine developed by Moderna; ChAdOx1 nCoV-19, vaccine developed by AstraZeneca; Ad26.COV2.S, vaccine developed by Janssen; NA, not applicable; SD, standard deviation; MSK, musculoskeletal; ENT, ear nose throath.
*New-onset IMID versus No new-onset IMID. P values were calculated with χ2 test or Mann-Withney U test as needed.
†This refers to the dose(s) received prior to the booster vaccination.
‡Booster dose was BNT162b2 in 2/8 patients and mRNA-1273 in 6/8 patients.
ENT, ears, nose and throat; MSK, musculoskeletal; N, number; NA, not applicable; SD, standard deviation.